INTRODUCTION
============

Efficient transcription in eukaryotes requires interplay between the RNA polymerase II (pol II) transcription machinery and factors regulating modification of the chromatin (reviewed in: [@B1]). Tri-methylation of lysine 4 on histone H3 (H3K4) occurs co-transcriptionally ([@B2]) and is strongly correlated with transcriptional activity ([@B3]). H3K4 methylation is mediated by the Set1p histone methyltransferase (HMT) complex in yeast ([@B4; @B5; @B6; @B7]). In recent years, several factors required for this modification have been identified. It is now apparent that ubiquitylation of histone H2B is necessary for methylation of H3K4 by Set1p ([@B8],[@B9]) and of H3K79 by Dot1p ([@B10]). H2B ubiquitylation is mediated by the Bre1p-Rad6p E3-E2 pair ([@B11],[@B12]).

The Bur1/2 kinase complex is involved in transcription elongation. This CDK--cyclin pair can phosphorylate the C-terminal domain (CTD) of the largest subunit of pol II *in vitro* ([@B13]), but it does not seem to contribute to CTD phosphorylation *in vivo* ([@B14]). This kinase complex is required for H2B ubiquitylation and H3K4 tri-methylation ([@B15]), which may involve direct phosphorylation of Rad6p ([@B16]). Interestingly, mono- and di-methylation of H3K4 are not affected by *BUR1/2* mutations ([@B15]). Like the Bur1/2 complex, the PAF complex is implicated in transcription elongation and is essential for efficient H2B ubiquitylation and H3K4 methylation, but not for recruitment of Rad6p ([@B17],[@B18]). The PAF complex consists of five subunits (Paf1p, Rtf1p, Ctr9p, Leo1p and Cdc73p) and interacts with pol II ([@B19],[@B20]). *BUR2* is required for efficient PAF complex recruitment to chromatin, but the mechanism by which this occurs remains unclear ([@B15],[@B16]).

The evolutionarily conserved Ccr4-Not complex is composed of nine core subunits and is implicated in various steps of mRNA production and processing (reviewed in: [@B21],[@B22]). The genes encoding the Not-proteins (*NOT1-5*) were initially identified as negative regulators of transcription initiation. Support for such a role was provided by the observation that several mutations in *NOT* genes suppress a temperature-sensitive allele of *SRB4* ([@B23]), which encodes an essential subunit of the mediator co-activator complex ([@B24]). However, various reports also indicate a positive role for the Ccr4-Not complex ([@B25; @B26; @B27]). For example, this complex is required for transcription of *RNR* genes following DNA damage or replication stress ([@B27]). Genetic and physical interactions of Ccr4-Not complex components with transcription initiation and elongation factors have been described (reviewed in: [@B21],[@B22]). Besides this, Ccr4p and Caf1p represent the major mRNA deadenylases in yeast ([@B28]).

To further investigate the role of the Ccr4-Not complex, we performed a genome-wide screen to find non-essential gene deletion mutants that display synthetic genetic interactions with a deletion of *NOT4*. Here, we describe genetic interactions of components of the Ccr4-Not complex with *BUR2* and *BUR1*. We found that the *NOT* genes are required to specifically facilitate tri-methylation, but not mono- or di-methylation, of H3K4. Deletion of *NOT4* reduced both histone H2B ubiquitylation and PAF complex recruitment, but did not affect Bur1/2 activation or recruitment. Taken together, our results show a novel role for the Ccr4-Not complex in chromatin modification and suggest a mechanism by which it contributes to positive regulation of transcription.

MATERIALS AND METHODS
=====================

Yeast genetics, media and plasmids
----------------------------------

The yeast strains used in this study and their relevant genotypes are indicated in [Table 1](#T1){ref-type="table"}. Knock-out, TAP- and mycAVI-tagged strains were constructed by homologous recombination of a PCR product and verified by PCR, phenotypic and/or western blot analysis. Cells were routinely cultured in YPD or SC medium lacking the appropriate amino acids. The *GAL1*-LacZ fusion and pGR422 plasmids have previously been described ([@B29],[@B30]). The pRS306-based *NOT4* integrative vector was previously published ([@B27]). Table 1.*Saccharomyces cerevisiae* strains used in this studyStrainGenotypeSourceBY4741MATa *his3Δ1 leu2Δ0 met15Δ0 ura3Δ0*EUROSCARFKMY57Isogenic to BY4741 except *not3:KanMX*EUROSCARFKMY58Isogenic to BY4741 except *not4:KanMX*EUROSCARFKMY59Isogenic to BY4741 except *not5:KanMX*EUROSCARFKMY60Isogenic to BY4741 except *caf1:KanMX*EUROSCARFKMY61Isogenic to BY4741 except *caf40:KanMX*EUROSCARFKMY62Isogenic to BY4741 except *caf130:KanMX*EUROSCARFKMY107Isogenic to BY4741 except *ccr4:KanMX*EUROSCARFKMY108Isogenic to BY4741 except *caf4:KanMX*EUROSCARFKMY109Isogenic to BY4741 except *caf16:KanMX*EUROSCARFKMY110Isogenic to BY4741 except *caf120:KanMX*EUROSCARFMY1MATa *ura3-52, trp1-Δ1, leu2::PET56 gal2 gcn4-Δ1*([@B48])KMY102Isogenic to MY1 except *not1-1*Gift from M. CollartKMY114Isogenic to MY1 except *not1-2*Gift from M. CollartKMY103Isogenic to MY1 except *not2:KanMX*Gift from M. CollartKMY104Isogenic to MY1 except *not3:KanMX*Gift from M. CollartKMY97Isogenic to MY1 except *not4:KanMX*Gift from M. CollartKMY105Isogenic to MY1 except *not5:KanMX*Gift from M. CollartW303-1BMATα *leu2-3,112 his3-11 trp1-1 can1-100 ade2-1 ura3-1*([@B52])KMY2Isogenic to W303-1B except *not4:KanMX*([@B53])UCC7164MATa *ade2Δ::hisG his3Δ200 leu2Δ0 lys2Δ0 met15Δ0 trp1Δ63 ura3Δ0 ADE2-TEL-VR adh4::URA3-TEL-VIIL*Gift from F. van LeeuwenUCC7183Isogenic to UCC7164 except *dot1:KanMX*Gift from F. van LeeuwenKMY81Isogenic to UCC7164 except *not4:KanMX*This workKMY161Isogenic to BY4741 except *bur2:KanMX*EUROSCARFKMY162Isogenic to BY4741 except *spp1:KanMX*EUROSCARFYSB787MATa *bur1:HIS3 ura3-52 leu2Δ1 trp1Δ63 his3Δ200 lys2Δ202 (pRS316-BUR1)*([@B14])KMY140Isogenic to YSB787 except *not4:KanMX*This workKMY40MATα *mfa1Δ::MFA1pr-HIS3 his3Δ1 ura3Δ0 lys2Δ0 can1Δ not4:URA3*This workKMY133*not4:LEU2 CTR9-HA6:TRP1*, seggregant of YJJ1753 X *not4:LEU2* (KMY73)This workKMY136Isogenic to KMY133 except *not4:LEU2::NOT4:URA3*This workYZS276*hta1-htb1Δ::LEU2 hta2-htb2Δ HTA-Flag-HTB1:HIS3*([@B9])YZS277Isogenic to YZS276 except *HTA-Flag-htb1-K123R*([@B9])YNL019Isogenic to YZS276 except *not4Δ:KanMX*Gift from B. StrahlYSB770MATa *BUR1-HA3:TRP1 ura3-52 leu2Δ1 trp1Δ63 his3Δ200 lys2Δ202*([@B14])YSB813MATa *BUR2-HA3:TRP1 ura3-52 leu2Δ1 trp1Δ63 his3Δ200 lys2Δ202*([@B14])KMY199Isogenic to YSB770 except *not4Δ:KanMX*This workKMY41Isogenic to KMY2 except *not4L35A:URA3*([@B29])KMY200Isogenic to YSB813 except *not4Δ:KanMX*This workKMY201MATα *mfa1Δ::MFA1pr-HIS3 bur2Δ:URA3 his3Δ1 ura3Δ0 lys2Δ0 can1Δ*This work

Phenotypic assays
-----------------

Here, 10- or 5-fold serial dilutions of the indicated strains were spotted on SC-U −/+ 6-azauracil (6-AU) (100 μg/ml) or SC −/+ 5FOA (0.1%). For the 6-AU sensitivity assay, cells were transformed with pRS316. Growth at 30°C was assessed after 3--4 days.

*In vivo* elongation assay
--------------------------

Cells transformed with the *GAL1*-LacZ plasmid were grown in SC-U medium containing 2% raffinose overnight, collected and subsequently shifted to a medium containing 2% galactose. Samples were taken at the indicated time points. RNA extraction and northern blot analysis were performed as described previously ([@B27]). PCR product probes spanning the ORFs were radiolabeled using the Redi-prime II kit (Invitrogen).

Western blotting and antibodies
-------------------------------

Samples were taken from cells grown in YPD, and extracts were prepared as described previously ([@B31]). Proteins were separated by SDS-PAGE and analyzed by western blot. Antibodies against H3K4me1 (Ab8895), H3K4me2 (Ab7766), H3K4me3 (Ab8580), H3K79me3 (Ab2621) and the C-terminus of H3 (Ab1791) were obtained from Abcam. H3K36me2 (\#07--369) and H3K79me2 (\#07--366) antibodies were from Upstate Biotechnology. TBP antiserum was a kind gift from P.A. Weil. Antibodies H5 and H14 were used to detect the serine 2, serine 5 phosphorylated forms of the CTD of RNA pol II. The CTD-specific antibody 8WG16 was used to detect RNA pol II. TAP-tagged proteins were detected using IgG-peroxidase conjugates. Antibodies against the HA-tag (12CA5 and 3F10) or the FLAG-tag (M2, sigma) were used to detect Ctr9-HA, Bur1-HA, Bur2-HA and FLAG-H2B, respectively. Immunoblots in [Figure 2](#F2){ref-type="fig"}B were quantified using ImageQuant software and represented as fraction of WT after normalization on total H3 levels.

Chromatin immunoprecipitation (ChIP)
------------------------------------

Cell cultures and extract preparation were essentially performed as described previously with minor modifications ([@B27]). Briefly, protein A-coupled agarose beads were incubated with the antibodies indicated above for 30 min at 4°C, washed and subsequently incubated with extracts of cross-linked cells for 2--3 h at 4°C. Beads were washed, DNA eluted and cross-links reversed at 65°C overnight. DNA was isolated using a PCR purification kit (Qiagen) and analyzed by SYBR-green-based quantitative PCR analysis. Not4-mycAVI was purified using streptavidin-coated Dyna-beads (Dynal) and subjected to stringent washing conditions (3% SDS in TE) before reverse cross-linking. Further analysis was performed as above. Data is represented as percentage of input with a region from the HMR locus as a control.

Northern blot analysis and reverse transcriptase qPCR
-----------------------------------------------------

RNA extraction and Northern blots were performed as described previously ([@B27]). Equal amounts of total RNA were used to prepare cDNA using random hexamers and the SuperScript II kit (InVitrogen) according to the manufacturer\'s protocol. A dilution series of genomic DNA was used to determine the cDNA levels by SYBR-green-based quantitative PCR analysis.

Tandem affinity purification
----------------------------

TAP-tag-mediated protein purifications were performed essentially as described ([@B32]). Briefly, 20 l of YPD culture was grown to OD600 ∼ 2--3, washed and lysed in E-buffer (20 mM HEPES-KOH pH 8, 350 mM NaCl, 10% glycerol, 0.1% Tween-20). Lysates were cleared by centrifugation in a Beckman 50.2Ti rotor (45 000 r.p.m., 45 min, 4°C). An aliquot of lysate was used for purification over a 200 μl IgG sepharose column (IgG-sepharose fast flow, Pharmacia). Proteins were bound by rotating at 4°C for 2 h and subsequently washed with 35 ml E-buffer and 10 ml TEV protease cleavage-buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 0.1% Tween-20, 0.5 mM EDTA and 1 mM DTT). TEV protease (100 U) cleavage was performed in 1 ml at 18°C for 2 h. The TEV eluate was bound to 100 μl calmodulin affinity resin (Stratagene) in binding buffer (10 mM Tris pH 8, 150 mM NaCl, 1 mM MgAc, 1 mM imidazole, 2 mM CaCl~2~, 0.1% Tween-20, 10% glycerol and 10 mM β-mercaptoethanol) rotating at 4°C for 1 h. The column was washed with 25-ml binding buffer and bound proteins were recovered in elution buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM MgAc, 1 mM imidazole, 2 mM EGTA, 0.1% Tween-20, 10% glycerol and 10 mM β-mercaptoethanol). A fraction of the purified proteins was precipitated as described ([@B33]), separated on a 4--12% SDS-PAGE gradient gel (NuPage, Invitrogen), stained with Biosafe (BioRad) and processed for mass spectrometric analysis.

Tandem mass spectrometry
------------------------

In-gel proteolytic digestion of Coomassie-stained bands was performed essentially as described ([@B34]), using trypsin (Roche). Samples were subjected to nanoflow liquid (LC) chromatography (Agilent 1100 series) and concentrated on a C18 precolumn (100 μm ID, 2 cm). Peptides were separated on an analytical column (75 μM ID, 20 cm) at a flow rate of 200 nl/min with a 60 min linear acetonitrile gradient from 0 to 80%. The LC system was directly coupled to a QTOF Micro tandem mass spectrometer (Micromass Waters, UK). A survey scan was performed from 400 to 1200 a.m.u./s and precursor ions were sequenced in MS/MS mode at a threshold of 150 counts. Data were processed and subjected to database searches using Proteinlynx Global Server version 2.1 (Micromass, UK) or MASCOT software (Matrixscience) against SWISSPROT and the NCBI non-redundant database, with a 0.25-Da mass tolerance for both precursor ion and fragment ion. The identified peptides were confirmed by manual interpretation of the spectra.

*In vitro* methylation assay
----------------------------

Set1p complexes (10--20 μl TEV eluate) from WT or *not4*Δ cells were incubated with 10 μg purified histones (Sigma) or 2.5 μg H3K4 (methylated) tail peptides (Abcam, Ab7228, Ab1340, Ab7768 and Ab1342, respectively), 1.5 μCi ^3^H-S-adenosyl methionine in buffer (50 mM Tris-HCl pH 8, 10 mM MgCl~2~ and 10 mM β-mercaptoethanol) at 30°C for 30 min. After separation by SDS-PAGE, the gels were dried and exposed to X-ray films.

RESULTS
=======

The Ccr4-Not and Bur1/2 complexes interact genetically
------------------------------------------------------

To obtain more insight into the function of the Ccr4-Not complex, we performed a genome-wide survey to find synthetic genetic interactions with a null allele of *NOT4*. We identified several interactions with genes implicated in transcription elongation by RNA polymerase II (K.W.M., A.I. and H.T.M.T., submitted for publication). Most striking was the interaction between *NOT4* and *BUR2*. Subsequent tetrad analysis of double deletions of *BUR2* and Ccr4-Not components showed additional synthetic lethal interactions with *NOT2* and *CCR4*, but not with *NOT3, CAF40* and *CAF130* ([Figure 1](#F1){ref-type="fig"}A). Notably, deletion of the gene encoding Bur1p, the cyclin-dependent kinase partner of Bur2p, results in a strong growth defect and this strain was not represented in the library used for the genetic screen. To test a genetic interaction between *NOT4* and *BUR1* in a direct manner, we introduced a plasmid-based WT or temperature-sensitive mutant of *BUR1* (*bur1-23*) into either *NOT4* or *not4*Δ strains in which the sole copy of *BUR1* was expressed from a *URA3* plasmid (pRS316). Plasmid-shuffle analysis demonstrated synthetic lethality between a deletion of *NOT4* and *bur1-23* ([Figure 1](#F1){ref-type="fig"}B). Figure 1.Ccr4-Not complex components genetically interact with *BUR1* and *BUR2* and play a role in transcription elongation. (**A**) Tetrad analysis of *bur2*Δ (KMY201) and BY4741 Ccr4-Not deletion or *not4*Δ (KMY40) BY4741*bur2*Δ diploids. Circles indicate double knock-out strains. Relevant genotypes of the haploid strains obtained are indicated (**B**) Plasmid-shuffle analysis of *bur1-23* and *not4*Δ double-mutant strains containing pRS316-*BUR1*. Here, 10-fold serial dilutions of the indicated strains were spotted on SC and SC containing 0.1% 5FOA. (**C**) 6-Azauracil sensitivity assay. Here, 10-fold serial dilutions of the indicated strains were spotted on SC-U and SC-U containing 6-AU (100 μg/ml). (**D**) *In vivo* transcription elongation analysis of a long GC-rich reporter. BY4741 and *not4*Δ (KMY58) strains transformed with a *GAL1pr*-LacZ plasmid (pGR422) were grown in a medium containing raffinose and shifted to a medium containing galactose for 0, 45 and 90 min. Northern blot analysis on LacZ and endogenous *GAL1* mRNA was performed using 18S rRNA as a control. Figure 2.Specific requirement for the *NOT* genes for global H3K4 tri-methylation. (**A**) Histone H3K4 mono-, di- and tri-methylation levels were determined in lysates from logarithmically growing BY4741-based *CCR4-NOT* gene deletion strains. Protein extracts of the indicated strains were separated by SDS-PAGE (15%) and subjected to western blotting using H3K4me1-, H3K4me2- and H3K4me3- specific antibodies. TBP levels were determined as a loading control. (**B**) MY1-based *NOT* mutant strains were used to determine H3K4me2, H3K4me3 and total H3 levels as in (A). H3K4me3 and H3K4me2 levels were quantified using ImageQuant software and represented as relative to WT after normalization to total H3 levels. (**C**) Direct comparison of H3K4me2 and H3K4me3 levels in BY4741, *not4*Δ, *not5*Δ and *spp1*Δ strains. Analysis was performed as in (A). (**D**) H3K79me2 and H3K79me3 levels in the indicated BY4741 deletion strains. Analysis was performed as in (A). (**E**) Silencing assay using strains, containing *URA3* in the telomeric region of the left arm of chromosome 7, lacking *NOT4* or *DOT1*. Cells were spotted in 5-fold serial dilutions on SC plates or on SC plates containing 5FOA.

Considering that the Bur1/2 complex was found to play a role in transcription elongation ([@B13],[@B14]), *not4*Δ and *bur2*Δ strains were first tested for sensitivity to 6-AU. In agreement with observations linking the Ccr4-Not complex to transcription elongation ([@B25]), cells lacking *NOT4* or *BUR2* were 6-AU sensitive ([Figure 1](#F1){ref-type="fig"}C). Strikingly, a strict correlation was observed between the 6-AU sensitivity of Ccr4-Not gene deletions and synthetic lethality with *BUR2* ([@B25]). This suggests that this synthetic lethality may be due to defects in transcription elongation. To extend these observations, we investigated requirement of *NOT4* for transcription of a long and GC-rich reporter gene. This experimental setup has previously been used to study transcription elongation defects ([@B29],[@B35]). [Figure 1](#F1){ref-type="fig"}D shows that in cells lacking *NOT4*, the *GAL1*-promoter-driven LacZ reporter gene was inefficiently transcribed, whereas the endogenous *GAL1* gene was expressed to WT levels. Taken together, these experiments show that Ccr4-Not complex components genetically interact with both *BUR2* and *BUR1* and confirm a role for this complex in transcription elongation ([@B25]).

Efficient H3K4 tri-methylation is dependent on the Ccr4-Not complex
-------------------------------------------------------------------

The Bur1/2 complex is implicated in the regulation of tri-methylation of H3K4 ([@B15],[@B16]). The genetic interactions between *NOT4, BUR2* and *BUR1* prompted us to investigate the involvement of the Ccr4-Not complex in this process by analyzing global levels of H3K4me1, H3K4me2 and H3K4me3 using specific antibodies. Strains deleted for *NOT4* or *NOT5* displayed a strong reduction of H3K4 tri-methylation, but not of mono- or di-methylation ([Figure 2](#F2){ref-type="fig"}A). However, deletion of *NOT3, CCR4* or any of the Ccr4-associated factors (*CAF*s) did not give rise to this effect ([Figure 2](#F2){ref-type="fig"}A). It is worth noting that several *CCR4-NOT* gene deletion phenotypes are not evident in *not3*Δ cells ([@B26],[@B27]; [Figure 1](#F1){ref-type="fig"}A and data not shown).

To extend these observations, two mutant alleles of the essential *NOT1* gene and deletions of the other *NOT* genes were analyzed in a different genetic background. Under permissive conditions, both *not1* alleles displayed a clear decrease in overall H3K4me3 levels (50--70% reduction as shown by quantification of the results), whereas growth of these cells was not affected. Moreover, deletion of *NOT2, NOT4* or *NOT5* reduced H3K4me3 levels (86--94% reduction; [Figure 2](#F2){ref-type="fig"}B). In contrast, only a slight decrease in H3K4me2 levels was observed in these strains ([Figure 2](#F2){ref-type="fig"}B). It has been reported that Set1p complexes lacking Spp1p are unable to tri-methylate H3K4 ([@B36],[@B37]). We found that deletion of *NOT4* or *NOT5* resulted in H3K4me3 levels comparable to deletion of *SPP1* ([Figure 2](#F2){ref-type="fig"}C). In addition, H3K79me2 and H3K79me3 levels in extracts of *CCR4-NOT* deletion strains were essentially not affected ([Figure 2](#F2){ref-type="fig"}D), although a minor decrease in H3K79me2 in cells lacking *NOT5* was observed. As expected, deletion of *RAD6* led to a severe decrease in H3K79me2 and H3K79me3 levels ([@B10]).

These results suggest a specific requirement for the *NOT* genes for efficient H3K4 tri-methylation. Similarly, *BUR1* and *BUR2* are required for tri-methylation, but not for mono- or di-methylation of H3K4 ([@B15]). Dot1p, the HMT specific for methylation of H3K79 plays an important role in silencing of genes near telomeres ([@B38]). Deletion of *SET1* results in a similar defect in this process ([@B4],[@B39]). Notably, integrity of telomeric silencing was not affected by deletion of *NOT4* ([Figure 2](#F2){ref-type="fig"}E). This is consistent with the notion that H3K4me3 is not required for telomeric silencing ([@B37]) and our observation that *NOT4* is specifically required for tri-methylation of H3K4.

Taken together, these results show that the *NOT*-module of the Ccr4-Not complex is essential for efficient H3K4 tri-methylation but not for H3K79 methylation or telomeric silencing.

H3K4 tri-methylation on the *PYK1* locus is affected by deletion of *NOT4*
--------------------------------------------------------------------------

To investigate the role of *NOT4* in the regulation of histone H3 methylation on active genes, ChIP experiments on the constitutively active and highly expressed *PYK1* gene were performed using extracts of WT and *not4*Δ cells. Using specific antibodies H3K4me3, H3K4me2, H3K36me2 and H3K79me2 levels at the 5′ and the middle region of the *PYK1* ORF were examined ([Figure 3](#F3){ref-type="fig"}A--E). *Not4*Δ cells displayed a clear decrease in the level of H3K4me3 at the 5′ end of the *PYK1* ORF compared to WT ([Figure 3](#F3){ref-type="fig"}B), whereas H3K4me2 levels were much less affected by deletion of *NOT4* ([Figure 3](#F3){ref-type="fig"}C). Further analysis showed that H3K36me2 and H3K79me2 levels were not decreased in *not4*Δ cells ([Figure 3](#F3){ref-type="fig"}D and E). In addition, pol II occupancy was determined using antibodies against the CTD of Rpb1p as a measure for transcriptional activity. In parallel, *PYK1* and *TUB1* mRNA levels were measured by quantitative RT-PCR in WT and *not4*Δ cells. Both pol II association to the *PYK1* ORF and *PYK1* transcript levels were diminished in the absence of *NOT4* ([Figure 3](#F3){ref-type="fig"}F and G). Extending on these results, we determined the H3K4 methylation status of cells deleted for *NOT2*. Indeed, examination of *not2*Δ cells confirmed a requirement for *NOT2* in the regulation of H3K4me3 specifically ([Figure 3](#F3){ref-type="fig"}H and I). Notably, essentially identical results were obtained when analyzing the *PGK1* locus (data not shown), in line with a broader role for *NOT4* in regulating H3K4me3 levels. Figure 3.*NOT4* is required for H3K4 tri-methylation but not di-methylation of the *PYK1* ORF. (**A**) Schematic representation of the *PYK1* locus and the amplicons used in (B--H). (**B**) ChIP analysis of the *PYK1* ORF in BY4741 and *not4*Δ strains. Exponentially growing cells were subjected to ChIP analysis using H3K4me3 antibodies. (**C**) As in (A), using H3K4me2 antibodies. (**D**) As in (A), using H3K36me2 antibodies. (**E**) As in (A), using H3K79me2 antibodies. (**F**) As in (A), using CTD antibodies (8WG16). (**G**) Quantitative reverse-transcriptase PCR analysis of *PYK1* and *TUB1* mRNA levels in BY4741 WT and *not4*Δ strains. (**H**) ChIP analysis of H3K4me3 levels in MY1 WT and *not2*Δ cells. (**I**) ChIP analysis of H3K4me2 levels in MY1 WT and *not2*Δ cells. (**J**) Not4p is recruited to the 5′ region of the *PYK1* ORF. Strains expressing mycAVI-tagged Not4p were transformed with a BirA expression plasmid and subjected to ChIP analysis. Signals were normalized to an empty plasmid control.

To assess the direct involvement of Not4p in the regulation of *PYK1* expression, ChIP analysis using a chromosomally expressed tagged form of *NOT4* was performed. The encoded protein (Not4p-mycAVI) was biotinylated *in vivo* by co-expression of the *E. coli*-derived BirA biotin ligase ([@B40]). Phenotypic analysis indicated that the Not4p-mycAVI fusion protein was fully functional (data not shown). Streptavidin-coated beads were used to capture the biotinylated Not4 proteins from chromatin extracts of cells containing either a plasmid expressing BirA or an empty vector. Interestingly, Not4p was detected on the 5′ end of the *PYK1* ORF and the region spanning the TATA box ([Figure 3](#F3){ref-type="fig"}J), coinciding with the region targeted for tri-methylation by the Set1p complex (see [Figure 3](#F3){ref-type="fig"}B and H). Taken together, these ChIP experiments confirm the specificity of the H3K4me3 defect and indicate that Not4p is physically present on the 5′ region of the *PYK1* ORF. In addition, deletion of *NOT4* resulted in decreased pol II occupancy and transcript levels, suggesting direct regulation of *PYK1* expression by Not4p through tri-methylation of H3K4.

Decreased H3K4me3 levels in cells deleted for *NOT4* does not strictly correlate with a decrease in RNA polymerase II association
---------------------------------------------------------------------------------------------------------------------------------

The exact mechanism of recruitment of the Set1 complex to transcribing polymerase is not fully understood. However, it has been suggested that phosphorylation of serine 2 and 5 of the hepta-peptide repeat of the CTD of RNA pol II is important for this ([@B2],[@B7]). In this light, the global decrease of H3K4me3 in cells lacking *NOT4* could be a consequence of a global loss of RNA pol II CTD phosphorylation. Immunoblot analysis using antibodies against phosphorylated serine 2, serine 5 or total RNA pol II (H5, H14 and 8WG16, respectively) did not reveal a decrease of phosphorylation of these residues in extracts from WT and *not4*Δ cells (data not shown). This indicates that the role of *NOT4* in regulating H3K4me3 levels is independent of RNA pol II phosphorylation. Arguably, the loss of H3K4 tri-methylation could be a consequence, rather than a cause, of decreased RNA pol II recruitment. To address this issue we investigated the *HSP104* gene, which allowed determination of the level of H3K4me3 on a gene that is not decreased in transcription in *not4*Δ cells (data not shown). We observed a decrease of H3K4 tri-methylation of the promoter region of *HSP104*, albeit less pronounced than what was observed for *PYK1* ([Figure 4](#F4){ref-type="fig"}A). In addition, we found a small increase in RNA pol II occupancy, which is in line with a slightly increased transcription rate ([Figure 4](#F4){ref-type="fig"}A and data not shown). Indeed, previous observations suggest that H3K4 methylation is not a critical determinant of *HSP* gene expression ([@B41]). In conclusion, this result shows that a decrease in H3K4me3 in *not4*Δ cells is not a consequence of decreased RNA pol II association *per se*. Figure 4.Decreased H3K4me3 in *not4*Δ cells is not necessarily due to decreased RNA polymerase II loading (**A**) ChIP analysis of H3K4me3 and RNA pol II levels on the *HSP104* locus. Data are represented as relative to WT. ChIP efficiencies were 2--3% and 0.15--0.2% for H3K4me3 and 8WG16 antibodies, respectively. (**B**) Deletion of *NOT4* or *SPP1* lead to a similar decrease in H3K4me3 and transcript levels on the *PYK1* gene. Chromatin extracts of BY4741, *not4*Δ and *spp1*Δ strains were subjected to ChIP analysis using H3K4me3-specific antibodies. *PYK1* mRNA transcript levels are affected by deletion of *NOT4* or *SPP1. PYK1* mRNA in total RNA of BY4147, *not4*Δ and *spp1*Δ strains was analyzed by quantitative reverse-transcriptase PCR.

To further investigate the role of H3K4me3 in transcription, we compared the levels of H3K4me3 on the *PYK1* locus in WT, *not4*Δ and *spp1*Δ cells. As shown in [Figure 4](#F4){ref-type="fig"}B, this modification is decreased by deletion of *NOT4* or *SPP1* to comparable levels. In addition, deletion of *SPP1* gave rise to a decrease in mRNA levels reminiscent of deletion of *NOT4* ([Figure 4](#F4){ref-type="fig"}B). Similar reductions of mRNA levels were observed for the *PGK1* gene (data not shown). This suggests that the diminished *PYK1* and *PGK1* mRNA levels are a consequence of decreased H3K4 tri-methylation. Taken together, these experiments show that the reduction of H3K4me3 levels in *not4*Δ cells is not a direct result of reduced RNA pol II association.

*NOT4* is not required for HMT activity of the Set1p complex
------------------------------------------------------------

The observed effect on H3K4me3 levels in *not4*Δ cells could be the result of *NOT4* being required for transcription of genes encoding factors essential for Set1p complex integrity or activity. For instance, deletion of *SPP1* results in the formation of a Set1p complex that is unable to tri-methylate H3K4 ([@B16]). We investigated this by purifying the Set1p complex from WT and *not4*Δ strains via a TAP-tagged version of the Bre2p subunit. In addition, we tested mRNA expression levels of Set1p complex subunits by northern blot analysis in strains containing or lacking *NOT4*. This indicated that neither transcript levels of its subunits nor composition of the Set1p complex are significantly affected by deletion of *NOT4* ([Figure 5](#F5){ref-type="fig"}A and B). Notably, the additional bands present in the purification from *not4*Δ cells were found to be non-specific lysosomal proteins (data not shown), which probably relates to differences in protein concentration between the extracts from WT or *not4*Δ cells. Using soluble histones as substrate in an *in vitro* HMT assay, no intrinsic defect in the methylation activity of Set1p complexes purified from *not4*Δ cells could be detected ([Figure 5](#F5){ref-type="fig"}C). In addition, (pre-methylated) synthetic peptides were used to determine whether Set1 complexes purified from *not4*Δ cells were active in tri-methylation of a di-methylated substrate. Notably, Set1 complexes from WT and *not4*Δ cells were equally efficient in modifying this synthetic peptide ([Figure 5](#F5){ref-type="fig"}D). Figure 5.The H3K4me3 defect in *not4*Δ cells is independent of direct regulation of the Set1p complex. (**A**) mRNA levels of Set1p complex components. RNA was extracted from exponentially growing BY4741 and *not4*Δ and subjected to northern blot analysis using the indicated probes. (**B**) Subunit composition of purified Set1p complexes. Strains containing or lacking *NOT4* and expressing a TAP-tagged Bre2p were used to purify Set1p complexes (upper panel). Equal expression of Bre2-TAP proteins was checked by western blot analysis (lower panel). The indicated proteins were identified using LC-MS/MS. Several additional proteins were present in the *not4*Δ purification when compared to the WT. Mass spectrometry showed that these bands contained non-related lysosomal proteins. We consider this an artifact of the purification, likely caused by differences in the concentration of the lysates of the WT and *not4*Δ cells. (**C**) Histone methyl transferase assay using purified Set1p complexes. Increasing amounts of Set1p complex or a mock-purification control were use to methylate soluble histones (from calf thymus) *in vitro*. Samples were separated on a 15% SDS-PAA gel, stained with Coomassie, dried and exposed to an X-ray film. (**D**) *In vitro* methylation of synthetic pre-methylated histone H3-tail peptides. Pre-methylated peptides were used as substrates for *in vitro* methylation using Set1p complexes purified from WT or *not4*Δ cells. Samples were separated on a 20% SDS-PAA gel, dried and exposed to an X-ray film. Signals were quantified using ImageQuant software and represented as arbitrary units after background correction.

Taken together, these experiments show that the mechanism underlying the H3K4me3 defect in *not4*Δ cells is distinct from deregulation of the Set1p complex at the level of transcription, composition or intrinsic activity and specificity.

Deletion of *NOT4* reduces ubiquitylation of histone H2B and recruitment of the PAF complex
-------------------------------------------------------------------------------------------

H2B ubiquitylation is required for efficient H3K4 methylation ([@B16]). To investigate the role of Not4p in ubiquitylation of H2B, plasmid-based FLAG-tagged H2B was expressed in *not4*Δ cells. Ubiquitylated H2B could be detected in logarithmically growing WT cells, but H2B-ubiquitin levels were significantly decreased in cells lacking *NOT4*. As expected, ubiquitylated H2B could not be detected in cells expressing FLAG-tagged H2B-K123R ([Figure 6](#F6){ref-type="fig"}A, [@B39]). Interestingly, Not4p contains a RING-finger motif and displays ubiquitylation activity *in vitro* (K.W.M., A.I. and H.T.M.T., submitted for publication). Therefore, the H3K4me3 status was determined in cells expressing an inactive (L35A) mutant of Not4p as a measure for H2B ubiquitylation. The H3K4me3 defect of *not4*Δ cells was fully complemented by the L35A mutant of Not4p, suggesting that its RING-finger is not required for ubiquitylation of H2B ([Figure 6](#F6){ref-type="fig"}B). In addition, *in vitro* ubiquitylation assays indicated that H2B does not serve as a substrate for Not4p (data not shown). Figure 6.Deletion of *NOT4* diminishes H2B ubiquitylation and PAF complex recruitment. (**A**) *NOT4* is required for efficient H2B ubiquitylation. Extracts of the indicated strains carrying a FLAG-*HTB1* plasmid were separated on a 12.5% SDS-PAGE gel and subjected to western blot analysis using FLAG antibodies. The lower panel shows a shorter exposure of the same blot, indicating equal loading. (**B**) The ubiquitin-ligase activity of Not4p is not involved in the regulation of H3K4me3 levels. The H3K4 methylation status in extracts from cells expressing *NOT4* or *not4L35A* alleles from the endogenous *NOT4* locus and cells lacking *NOT4* were subjected to western blot analysis. (**C**) Ctr9-HA is equally expressed in *NOT4* and *not4*Δ cells. Strains expressing HA-tagged Ctr9p, containing or lacking *NOT4*, were used to determine Ctr9-HA levels by western blotting. H3K4me3 and TBP levels were used as controls. (**D** and **E**) *NOT4* is required for PAF complex recruitment to the *PYK1* and *PGK1* ORFs. Strains from (C) were subjected to ChIP analysis of the *PYK1* locus (amplicons are schematically depicted in upper panel). Exponentially growing cells were cross-linked and ChIPs were performed using anti-HA (12CA5) antibodies.

*In vivo*, H2B ubiquitylation is dependent on recruitment of the PAF complex to chromatin ([@B18]). To assess the role of Not4p in the recruitment of the PAF complex, strains expressing HA-tagged Ctr9p and containing or lacking *NOT4* were constructed. Ctr9-HA was expressed to equal levels in the two strains, whereas H3K4me3 levels were reduced in the *not4*Δ cells as expected ([Figure 6](#F6){ref-type="fig"}C). Extracts were prepared from exponentially growing cells and subjected to ChIP analysis. Whereas Ctr9-HA was readily detected in the ORFs of *PYK1* and *PGK1* in WT cells, binding was severely reduced in cells lacking *NOT4* ([Figure 6](#F6){ref-type="fig"}D and E). Taken together, these results show a requirement for *NOT4* in H2B ubiquitylation and a role in the regulation of PAF complex recruitment to the *PYK1* and *PGK1* genes to facilitate tri-methylation of H3K4.

The Ccr4-Not complex functions parallel to or downstream of the Bur1/2 kinase
-----------------------------------------------------------------------------

Chromatin association of the PAF complex depends on the Bur1/2 complex ([@B15],[@B16]). The requirement for *NOT4* for efficient PAF complex recruitment places the Ccr4-Not complex in the pathway containing the Bur1/2 kinase. To investigate this further, strains expressing HA-tagged Bur1p or Bur2p, containing or lacking *NOT4*, were constructed to determine occupancy of Bur1p and Bur2p. Expression of the HA-tagged versions of Bur1p and Bur2p was equal between WT and *not4*Δ cells ([Figure 7](#F7){ref-type="fig"}A). ChIP analysis with these strains showed that both Bur1p and Bur2p were found to associate with the *PYK1* and *PGK1* loci with similar efficiencies ([Figure 7](#F7){ref-type="fig"}B and C). In addition, *NOT4* is not required for the activation of the Bur1p kinase since the active phosphorylated form of Bur1p is readily detected in cells lacking *NOT4* ([Figure 7](#F7){ref-type="fig"}A). These results place the Ccr4-Not complex parallel to, or downstream of the Bur1/2 kinase and upstream of the PAF complex in a pathway leading to H3K4 tri-methylation. Figure 7.The Ccr4-Not complex functions downstream of or parallel to the Bur1/2 kinase. (**A**) Bur1-HA and Bur2-HA are equally expressed in WT and *not4*Δ cells. Extracts of cells expressing HA-tagged Bur1p or Bur2p containing or lacking *NOT4*, or a non-tagged control, were subjected to western blot analysis using antibodies against the HA-tag, H3K4me3 and TBP. (**B**) Recruitment of the Bur1/2 complex to the *PYK1* locus does not depend on *NOT4*. WT and *not4*Δ cells expressing HA-tagged Bur1p or Bur2p, and a no-tag control, were subjected to ChIP analysis using anti-HA (12CA5) antibodies (amplicons are schematically depicted in the upper panel). (**C**) As in (B), except that the analysis was performed for the *PGK1* locus.

DISCUSSION
==========

The Ccr4-Not complex is involved in mRNA biogenesis at different levels (reviewed in [@B21],[@B22]). Here, we show that the *NOT* genes, in contrast to *CCR4* and the *CAF* genes, are required for global and gene-specific tri-methylation of H3K4 ([Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). In addition, we found that the Ccr4-Not complex is functionally linked to the Bur1/2 kinase complex ([Figure 1](#F1){ref-type="fig"}), which is also specifically required for H3K4 tri-methylation ([@B20]). The mechanism by which the Ccr4-Not complex is involved in this histone modification is independent of direct regulation of the Set1p histone methyltransferase complex ([Figure 5](#F5){ref-type="fig"}). Instead, the Ccr4-Not complex functions parallel to or downstream of Bur1/2p at the level of PAF complex recruitment, resulting in decreased ubiquitylation of H2B, in cells lacking *NOT4* ([Figure 8](#F8){ref-type="fig"}). Taken together, our results provide a detailed study of the role of the Ccr4-Not complex in the regulation of global H3K4 tri-methylation. Further, they confirm a functional distinction between the cytoplasmic deadenylase activity of the Ccr4p-Caf1p module and the nuclear function of the Not-proteins of the Ccr4-Not complex ([@B42]). Figure 8.A model indicating how the Ccr4-Not complex may function in establishing H3K4 tri-methylation through regulation of PAF complex recruitment. The Ccr4-Not complex could be controlled by the Bur1/2 kinase to facilitate PAF complex recruitment (downstream). Alternatively, the Bur1/2 and Ccr4-Not complexes function in distinct pathways sharing several components and independently regulate PAF complex recruitment (parallel).

Cooperation between the Bur1/2 and Ccr4-Not complexes in establishing H3K4 tri-methylation
------------------------------------------------------------------------------------------

The Bur1/2 complex was shown to be required for H3K4 tri-methylation ([@B15]) and this involves phosphorylation of Rad6p ([@B16]). The genetic interactions between genes encoding Ccr4-Not complex subunits (*NOT2, NOT4* and *CCR4*) and *BUR1* and *BUR2*, suggest a role for this complex in transcription elongation ([Figure 1](#F1){ref-type="fig"}). Interestingly, deletions of several Ccr4-Not components were shown to exhibit 6-AU sensitivity, suggesting such a role ([@B25]). Notably, a strict correlation between the published 6-AU sensitivity for Ccr4-Not components and synthetic lethality with *BUR2* was observed. Since the Bur1/2 complex was shown to be involved in the regulation of H3K4me3 levels ([@B15]), we determined the levels of various histone H3 lysine methylation marks in cells lacking genes encoding Ccr4-Not components. In contrast to the *NOT*-gene deletion strains, decreased H3K4me3 levels were not observed in *ccr4*Δ cells ([Figure 2](#F2){ref-type="fig"}), suggesting that Ccr4p and the Not-module contribute to transcription elongation by distinct mechanisms. An alternative explanation could be that deletion of Ccr4-Not components and *BUR2* results in partial loss of subsequent activities within the same pathway, ultimately resulting in the observed synthetic lethality.

Insight into the mechanism by which the Not-proteins function in the pathway leading to H3K4 tri-methylation comes from the observations that PAF complex recruitment and subsequent efficient ubiquitylation of H2B, but not Bur1/2 complex recruitment, are dependent on the presence of *NOT4*. However, other modifications such as H3K4 mono- and di-methylation or H3K79 di- and tri-methylation were not affected by deletion of *NOT4*. These results suggest a model in which the pathways leading to H3K4 and H3K79 methylation bifurcate upstream of the Ccr4-Not complex and are in agreement with a recent report showing that *BUR2* is only required for H3K4 tri-methylation ([@B15],[@B16]). Alternatively, the residual degree of ubiquitylated H2B that is observed in cells lacking *NOT4* may be sufficient to sustain H3K79me2/3 and H3K4me2, but not H3K4me3 levels. Support for this hypothesis comes from the observation that cells deleted for *PAF1* show significant levels of H3K4 di-methylation but not tri-methylation ([@B43], data not shown).

Regulation of H3K4 tri-methylation by the Ccr4-Not complex and involvement of the PAF complex
---------------------------------------------------------------------------------------------

The Set1p complex (or COMPASS) represents the sole HMT for H3K4 in yeast ([@B4; @B5; @B6]). The observation that transcription, subunit composition, activity and specificity of the Set1p complex are not affected by Not4p suggests that the Ccr4-Not complex functions further upstream in a pathway regulating H3K4 tri-methylation. The finding that Not4p is physically present at the 5′ region of the *PYK1* ORF, coinciding with the H3K4 tri-methylation mark and the PAF complex, suggests a direct role for the Ccr4-Not complex in the regulation of this modification. Possibly, recruitment of the Ccr4-Not complex to this region aids localization of the H3K4me3 mark. Another important insight into the mechanism by which the Ccr4-Not complex controls H3K4me3 levels comes from the observation that PAF complex recruitment is severely decreased in the absence of *NOT4*, whereas Bur1p and Bur2p recruitment and activation are not affected ([Figures 6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}). The Bur1/2 kinase is known to act upstream of PAF complex recruitment ([@B15]). Thus, the Ccr4-Not complex could either act downstream of the Bur1/2 kinase, or in a parallel pathway to regulate PAF complex recruitment ([Figure 8](#F8){ref-type="fig"}). It is interesting to note that both Not3p and Not5p are phospho-proteins ([@B44]), but the connection with Bur1/2 complex remains unexplored. In the parallel pathway, the Bur1/2 and Ccr4-Not complexes would act independently of each other in the recruitment of the PAF complex to chromatin. Strikingly, deletion of *BUR2* or *NOT4* results in only a partial loss of H2B ubiquitylation, PAF complex recruitment and subsequent H3K4 tri-methylation ([@B15], [Figures 2](#F2){ref-type="fig"} and [6](#F6){ref-type="fig"}).

Previous experiments have physically linked the PAF complex and Ccr4p ([@B45]). However, we and others have failed to detect PAF complex members or Bur1p/2p in Ccr4-Not purifications ([@B46], data not shown). In addition, deletion of *PAF1* gives rise to an HU-sensitive phenotype and deregulation of *RNR* gene transcription ([@B47]). Intriguingly, this was also observed for deletions of *CCR4-NOT* genes ([@B27]) and deletion of *BUR2* (data not shown), suggesting a functional interplay between these complexes. Alternatively, alteration of other components of the histone code might also contribute to the regulation of H3K4me3 levels by the Ccr4-Not complex. Irrespective of this, it is clear that further experiments are required to elucidate the connections between the Ccr4-Not and PAF complexes.

Positive and negative regulation of transcription by the Ccr4-Not complex
-------------------------------------------------------------------------

Our results support a global role for the Ccr4-Not complex in the positive regulation of transcription. In addition, mutation of components of this complex results in derepression of a variety of genes ([@B26],[@B48]). These seemingly contradicting observations may be reconciled by recent findings of recognition of H3K4-methylated histones by PHD finger containing proteins ([@B49; @B50; @B51]). These domains are believed to recruit chromatin-modifying complexes, like NURF and the mSin3a-HDAC1 complex to H3K4-methylated chromatin ([@B49],[@B51]). Yeast contains 15 PHD fingers residing in a variety of chromatin-modifying complexes and these motifs display different relative affinities for H3K4me2 and H3K4me3 ([@B50]). Specific loss of H3K4 tri-methylation could therefore shift the balance of chromatin regulatory complexes at particular genes. It is unlikely that the sole function of the Ccr4-Not complex is regulation of H3K4 tri-methylation via recruitment of the PAF complex. Besides the well-documented role of the Ccr4p and Caf1p subunits in mRNA deadenylation, multiple observations indicate that the Not-proteins can directly affect TFIID function (reviewed in [@B21],[@B22]). This suggests that the Ccr4-Not complex integrates several steps of mRNA expression. The functional consequences of Ccr4-Not gene deletions are likely to be gene specific as suggested, for example, by our results on the *PYK1* and *HSP104* genes. Taken together, these findings provide an explanation for the observation that the Ccr4-Not complex can have both negative and positive effects on gene transcription.

In summary, we have identified a role for the Ccr4-Not complex in the regulation of H3K4 tri-methylation levels by acting parallel to or downstream of the Bur1/2 kinase to facilitate PAF complex recruitment and subsequent H2B ubiquitylation. These results provide a connection between the role of the Ccr4-Not complex in the regulation of transcription and histone methylation marks.
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